Published in Cancer Epidemiol on October 17, 2014
Maximal tachycardia and high cardiac strain during night shifts of emergency physicians. Int Arch Occup Environ Health (2017) 0.75
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost (2005) 2.03
Blood pressure, cerebral blood flow, and brain volumes. The SMART-MR study. J Hypertens (2010) 1.74
Relation between adiposity and hypertension persists after onset of clinically manifest arterial disease. J Hypertens (2012) 1.66
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med (2013) 1.66
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma. Respirology (2014) 1.64
The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J (2004) 1.59
High blood pressure is inversely related with the presence and extent of coronary collaterals. J Hum Hypertens (2005) 1.47
Arterial stiffness and progression of structural brain changes: The SMART-MR study. Neurology (2014) 1.43
Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study. J Vasc Surg (2009) 1.43
Blood pressure and progression of cerebral atrophy in patients with vascular disease. Am J Hypertens (2009) 1.41
Prothrombotic gene variation in patients with large and small vessel disease. Neuroepidemiology (2008) 1.40
Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis (2004) 1.38
Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke (2008) 1.33
Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol (2012) 1.21
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. J Am Coll Cardiol (2013) 1.13
Association between subcortical vascular lesion location and cognition: a voxel-based and tract-based lesion-symptom mapping study. The SMART-MR study. PLoS One (2013) 1.09
A pilot-study to identify the feasibility of an Internet-based coaching programme for changing the vascular risk profile of high-risk patients. Patient Educ Couns (2008) 1.06
The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr (2008) 1.04
Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. Atherosclerosis (2009) 1.01
Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol (2014) 1.01
Total cerebral blood flow, white matter lesions and brain atrophy: the SMART-MR study. J Cereb Blood Flow Metab (2007) 0.99
Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study. Cardiovasc Diabetol (2011) 0.99
Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg (2010) 0.99
Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy (2013) 0.98
Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J (2008) 0.97
Carotid stiffness indicates risk of ischemic stroke and TIA in patients with internal carotid artery stenosis: the SMART study. Stroke (2004) 0.96
Cerebral small-vessel disease and progression of brain atrophy: the SMART-MR study. Neurology (2012) 0.95
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. NPJ Prim Care Respir Med (2015) 0.95
Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int J Cardiol (2013) 0.93
Alcohol consumption and risk of recurrent cardiovascular events and mortality in patients with clinically manifest vascular disease and diabetes mellitus: the Second Manifestations of ARTerial (SMART) disease study. Atherosclerosis (2010) 0.93
Carotid atherosclerosis and progression of brain atrophy: the SMART-MR study. Ann Neurol (2011) 0.92
Coronary collateral circulation: the effects of smoking and alcohol. Atherosclerosis (2006) 0.92
White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. Cerebrovasc Dis (2009) 0.92
Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease. Stroke (2013) 0.90
Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease. Atherosclerosis (2015) 0.90
Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma. J Allergy Clin Immunol Pract (2014) 0.90
Self-rated health status as a risk factor for future vascular events and mortality in patients with symptomatic and asymptomatic atherosclerotic disease: the SMART study. J Intern Med (2012) 0.89
Carotid intima-media thickness is different in large- and small-vessel ischemic stroke: the SMART study. Stroke (2007) 0.89
Location of cerebrovascular and degenerative changes, depressive symptoms and cognitive functioning in later life: the SMART-Medea study. J Neurol Neurosurg Psychiatry (2011) 0.89
Influence of atherosclerosis on age-related changes in renal size and function. Eur J Clin Invest (2003) 0.89
Association of white matter lesions and lacunar infarcts with executive functioning: the SMART-MR study. Am J Epidemiol (2009) 0.88
Effect of cerebrovascular risk factors on regional cerebral blood flow. Radiology (2007) 0.88
Metabolic syndrome, prediabetes, and brain abnormalities on mri in patients with manifest arterial disease: the SMART-MR study. Diabetes Care (2014) 0.88
The risk of general and abdominal adiposity in the occurrence of new vascular events and mortality in patients with various manifestations of vascular disease. Int J Obes (Lond) (2011) 0.87
Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial disease-magnetic resonance study. Stroke (2015) 0.86
Arterial blood flow to the brain in patients with vascular disease: the SMART Study. Radiology (2006) 0.86
Blood pressure and progression of brain atrophy: the SMART-MR Study. JAMA Neurol (2013) 0.86
Short-acting β-agonist use as a marker of current asthma control. J Allergy Clin Immunol Pract (2013) 0.86
Silent brain infarcts in patients with manifest vascular disease. Stroke (2004) 0.85
Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patients. Atherosclerosis (2005) 0.85
Metabolic syndrome and vascular risk in patients with peripheral arterial occlusive disease. J Vasc Surg (2009) 0.85
Manual B-mode versus automated radio-frequency carotid intima-media thickness measurements. J Am Soc Echocardiogr (2009) 0.84
The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study. Diabet Med (2007) 0.84
Standard medical management in secondary prevention of ischemic stroke in China (SMART). Int J Stroke (2011) 0.84
Homocysteine and progression of generalized small-vessel disease: the SMART-MR Study. Neurology (2014) 0.83
Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol (2012) 0.83
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther (2011) 0.83
Location and progression of cerebral small-vessel disease and atrophy, and depressive symptom profiles: the Second Manifestations of ARTerial disease (SMART)-Medea study. Psychol Med (2011) 0.82
Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease. PLoS One (2014) 0.82
C-reactive protein and incident diabetes in patients with arterial disease. Eur J Clin Invest (2013) 0.82
Cognitive dysfunction and its clinical and radiological determinants in patients with symptomatic arterial disease and diabetes. J Neurol Sci (2009) 0.81
Prognostic significance of coronary collaterals in patients with coronary heart disease having percutaneous transluminal coronary angioplasty. Am J Cardiol (2005) 0.81
The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease. Atherosclerosis (2016) 0.81
A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular Prevention by Nurses Study (VENUS). Eur J Cardiovasc Prev Rehabil (2006) 0.81
Prothrombotic genetic variants and atherosclerosis in patients with cerebral ischemia of arterial origin. Atherosclerosis (2008) 0.81
Completeness of the circle of Willis and risk of ischemic stroke in patients without cerebrovascular disease. Neuroradiology (2015) 0.81
Cerebellar Cortical Infarct Cavities: Correlation With Risk Factors and MRI Markers of Cerebrovascular Disease. Stroke (2015) 0.80
Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases. Eur J Endocrinol (2012) 0.80
The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. Am Heart J (2007) 0.80
Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease. Obesity (Silver Spring) (2011) 0.80
Intra-abdominal fat and metabolic syndrome are associated with larger infrarenal aortic diameters in patients with clinically evident arterial disease. J Vasc Surg (2008) 0.80
Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population. Arterioscler Thromb Vasc Biol (2015) 0.80
Elevated levels of plasma homocysteine are associated with neurotoxicity. Atherosclerosis (2004) 0.79
Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. J Vasc Surg (2006) 0.79
Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart (2013) 0.79
Presence of the metabolic syndrome does not impair coronary collateral vessel formation in patients with documented coronary artery disease. Diabetes Care (2005) 0.79
The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg (2007) 0.79
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. Eur J Prev Cardiol (2012) 0.79
The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. Cardiovasc Diabetol (2016) 0.79
Hemoglobin, hematocrit, and changes in cerebral blood flow: the Second Manifestations of ARTerial disease-Magnetic Resonance study. Neurobiol Aging (2014) 0.78
Serum angiotensin-converting enzyme and recurrent vascular events. The SMART-MR study. Atherosclerosis (2012) 0.78
Blood pressure and white matter lesions in patients with vascular disease: the SMART-MR study. Curr Neurovasc Res (2009) 0.78
Increasing levels of TNFalpha are associated with increased brain perfusion. Atherosclerosis (2007) 0.78
Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study. Diabet Med (2011) 0.78
LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. Eur J Clin Invest (2013) 0.78
Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors (2016) 0.78
Brain volumes and risk of cardiovascular events and mortality. The SMART-MR study. Neurobiol Aging (2014) 0.77
Blood pressure and decline in kidney function in patients with atherosclerotic vascular disease: a cohort study. Am J Kidney Dis (2009) 0.77
Prothrombotic gene variants and mortality after cerebral ischemia of arterial origin. Neuroepidemiology (2011) 0.77
Prediction model with metabolic syndrome to predict recurrent vascular events in patients with clinically manifest vascular diseases. Eur J Prev Cardiol (2011) 0.77
Homocysteine level and cognitive function in patients with arterial disease: the second manifestations of ARTerial Disease Study. J Am Geriatr Soc (2006) 0.77
The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease. Diabetes Care (2015) 0.77